pal Archives - Cambridge Cognition

Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI.

16 November 2020 / Insights

Insights Back to resource centre 16 November 2020 Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI. Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional

Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI. Read More »

Guidance for including elderly patients in clinical trials

14 July 2020 / Insights

Insights Back to resource centre 14 July 2020 Guidance for including elderly patients in clinical trials Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines

Guidance for including elderly patients in clinical trials Read More »

6 tests for assessing cognition in Parkinson’s disease

18 December 2018 / Insights

Insights Back to resource centre 18 December 2018 6 tests for assessing cognition in Parkinson’s disease Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap. Parkinson’s disease is a complex

6 tests for assessing cognition in Parkinson’s disease Read More »

CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairments

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment

25 October 2018 / Insights

Insights Back to resource centre 25 October 2018 CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials. BackgroundDetecting the progression

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment Read More »